UA26846C2 - Рекомбіhаhтhий іhтерлейкіh-2 людиhи - Google Patents
Рекомбіhаhтhий іhтерлейкіh-2 людиhиInfo
- Publication number
- UA26846C2 UA26846C2 UA5010517A UA5010517A UA26846C2 UA 26846 C2 UA26846 C2 UA 26846C2 UA 5010517 A UA5010517 A UA 5010517A UA 5010517 A UA5010517 A UA 5010517A UA 26846 C2 UA26846 C2 UA 26846C2
- Authority
- UA
- Ukraine
- Prior art keywords
- recombinant human
- human interleukin
- human
- theirs
- mitogenic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
- C07K1/1133—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by redox-reactions involving cystein/cystin side chains
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Analytical Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Рекомбінантний інтерлейкін-2 (ІЛ-2) людини одержано із гранул продукту експресії бактеріальних клітин після трансформації їх вектором, що містить нативний ген ІЛ-2 людини шляхом солюбілізації у відновленому середовищі з хаотропним агентом та подальшим очищенням за допомогою осадження. Ця речовина володіє мітогенною, проліферативною, макрофагостимулюючою та індукуючою цитотоксичність моноядерних клітин активностями нативного ІЛ-2 людини.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR8810184A FR2635527B1 (fr) | 1988-07-28 | 1988-07-28 | Il2 humaine recombinante non glycosylee sous forme reduite, son procede d'obtention et son application comme medicament |
Publications (1)
Publication Number | Publication Date |
---|---|
UA26846C2 true UA26846C2 (uk) | 1999-12-29 |
Family
ID=9368873
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UA5010517A UA26846C2 (uk) | 1988-07-28 | 1989-07-27 | Рекомбіhаhтhий іhтерлейкіh-2 людиhи |
Country Status (21)
Country | Link |
---|---|
US (2) | US5874076A (uk) |
EP (1) | EP0353150B1 (uk) |
JP (1) | JP3016793B2 (uk) |
KR (1) | KR0131070B1 (uk) |
CN (1) | CN1036532C (uk) |
AT (1) | ATE110783T1 (uk) |
AU (1) | AU624625B2 (uk) |
DE (1) | DE68917826T2 (uk) |
DK (1) | DK370489A (uk) |
ES (1) | ES2058573T3 (uk) |
FI (1) | FI96209C (uk) |
FR (1) | FR2635527B1 (uk) |
HU (1) | HU207099B (uk) |
IE (1) | IE64232B1 (uk) |
IL (1) | IL90975A (uk) |
MX (1) | MX16912A (uk) |
NZ (1) | NZ230111A (uk) |
PT (1) | PT91295B (uk) |
RU (1) | RU2105011C1 (uk) |
UA (1) | UA26846C2 (uk) |
ZA (1) | ZA895419B (uk) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2660863B1 (fr) * | 1990-04-17 | 1994-01-21 | Roussel Uclaf | Utilisation d'un polypeptide ayant l'activite de l'interleukine 2 humaine pour preparer une composition pharmaceutique destinee au traitement de cancers primitifs de la plevre. |
FR2668368B1 (fr) * | 1990-10-30 | 1995-03-10 | Roussel Uclaf | Utilisation d'un polypeptide ayant l'activite de l'interleukine 2 humaine pour preparer une composition pharmaceutique destinee au traitement des tumeurs malignes epitheliales. |
ES2107449T3 (es) * | 1990-11-23 | 1997-12-01 | Roussel Uclaf | Procedimiento de preparacion de una proteina elegida entre las citoquinas, que comprende al menos un puente disulfuro intramolecular por oxidacion, a un ph inferior a 5,0 de la proteina recombinante reducida correspondiente. |
FR2671728B1 (fr) * | 1991-01-17 | 1995-01-20 | Roussel Uclaf | Utilisation d'un polypeptide ayant l'activite de l'interleukine 2 humaine pour la preparation de compositions pharmaceutiques destinees au traitement des pneumathorax. |
FR2684878B1 (fr) * | 1991-12-12 | 1994-02-11 | Roussel Uclaf | Composition pharmaceutique stabilisee d'il2 humaine recombinante non glycosylee sous forme reduite et son procede de preparation. |
US6470207B1 (en) * | 1999-03-23 | 2002-10-22 | Surgical Navigation Technologies, Inc. | Navigational guidance via computer-assisted fluoroscopic imaging |
US20050203578A1 (en) * | 2001-08-15 | 2005-09-15 | Weiner Michael L. | Process and apparatus for treating biological organisms |
RU2372356C2 (ru) * | 2003-08-07 | 2009-11-10 | Займоджинетикс, Инк. | Полипептид с антивирусной активностью, его получение и применение |
MX2020005041A (es) | 2017-11-21 | 2020-10-12 | Univ Leland Stanford Junior | Agonistas parciales de interleucina-2. |
IL294659A (en) | 2020-01-14 | 2022-09-01 | Synthekine Inc | Methods and preparations of il2 skewed mutants |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1341562C (en) * | 1982-03-31 | 2007-11-27 | Tadatsugu Taniguchi | Gene coded for interleukin-2 polypeptide, recombinant dna carrying the said gene, a living cell line possessing the recombinant dna, and method for producing interleukin-2 using the said cell |
US5643566A (en) * | 1982-09-23 | 1997-07-01 | Cetus Corporation | Formulation processes for lipophilic proteins |
US4518584A (en) * | 1983-04-15 | 1985-05-21 | Cetus Corporation | Human recombinant interleukin-2 muteins |
JPS60115528A (ja) * | 1983-11-28 | 1985-06-22 | Takeda Chem Ind Ltd | ヒトインタ―ロイキン―2蛋白質を含有する抗腫瘍用または免疫機能低下疾患治療用組成物 |
US4604377A (en) * | 1984-03-28 | 1986-08-05 | Cetus Corporation | Pharmaceutical compositions of microbially produced interleukin-2 |
US4569790A (en) * | 1984-03-28 | 1986-02-11 | Cetus Corporation | Process for recovering microbially produced interleukin-2 and purified recombinant interleukin-2 compositions |
DE3583880D1 (de) * | 1984-04-09 | 1991-10-02 | Takeda Chemical Industries Ltd | Stabile interleukin-2-zusammensetzung. |
US4654830A (en) * | 1984-11-27 | 1987-03-31 | Monolithic Memories, Inc. | Method and structure for disabling and replacing defective memory in a PROM |
US4690915A (en) * | 1985-08-08 | 1987-09-01 | The United States Of America As Represented By The Department Of Health And Human Services | Adoptive immunotherapy as a treatment modality in humans |
JPH0829113B2 (ja) * | 1986-11-11 | 1996-03-27 | 武田薬品工業株式会社 | ヒトインタ−ロイキン−2の製造法 |
-
1988
- 1988-07-28 FR FR8810184A patent/FR2635527B1/fr not_active Expired - Fee Related
-
1989
- 1989-07-14 IL IL9097589A patent/IL90975A/en unknown
- 1989-07-17 ZA ZA895419A patent/ZA895419B/xx unknown
- 1989-07-25 MX MX1691289A patent/MX16912A/es unknown
- 1989-07-26 DE DE68917826T patent/DE68917826T2/de not_active Expired - Lifetime
- 1989-07-26 AT AT89402124T patent/ATE110783T1/de not_active IP Right Cessation
- 1989-07-26 EP EP89402124A patent/EP0353150B1/fr not_active Expired - Lifetime
- 1989-07-26 ES ES89402124T patent/ES2058573T3/es not_active Expired - Lifetime
- 1989-07-27 JP JP1192769A patent/JP3016793B2/ja not_active Expired - Lifetime
- 1989-07-27 IE IE244389A patent/IE64232B1/en not_active IP Right Cessation
- 1989-07-27 DK DK370489A patent/DK370489A/da not_active Application Discontinuation
- 1989-07-27 UA UA5010517A patent/UA26846C2/uk unknown
- 1989-07-27 FI FI893587A patent/FI96209C/fi not_active IP Right Cessation
- 1989-07-27 NZ NZ230111A patent/NZ230111A/en unknown
- 1989-07-27 HU HU893827A patent/HU207099B/hu not_active IP Right Cessation
- 1989-07-27 PT PT91295A patent/PT91295B/pt not_active IP Right Cessation
- 1989-07-28 CN CN89106242A patent/CN1036532C/zh not_active Expired - Fee Related
- 1989-07-28 AU AU39024/89A patent/AU624625B2/en not_active Ceased
- 1989-07-28 KR KR1019890010832A patent/KR0131070B1/ko not_active IP Right Cessation
-
1992
- 1992-01-08 RU SU5010517A patent/RU2105011C1/ru active
-
1995
- 1995-10-17 US US08/544,092 patent/US5874076A/en not_active Expired - Fee Related
-
1996
- 1996-02-12 US US08/601,434 patent/US5814314A/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE3688109D1 (en) | Fsh. | |
AU661901B2 (en) | Protein C derivatives | |
AU698043B2 (en) | Recombinant cells from the monocyte-macrophage cell line for gene therapy | |
ES8602121A1 (es) | Procedimiento para producir un vehiculo de expresion para la formacion de uroquinasa humana | |
MY111402A (en) | Novel uses of il-4 and/or il-10, and antibodies against the same | |
HU9201712D0 (en) | A mammalian cytokine, il-11 | |
IL110284A0 (en) | Viral vectors and their use in gene therapy | |
UA26846C2 (uk) | Рекомбіhаhтhий іhтерлейкіh-2 людиhи | |
HK206196A (en) | Acid-labile subunit (ALS) of insulin-like-growth factor (IGF) binding protein complex | |
AU5168099A (en) | Use of novel agents inducing cell death in synergy with interferons | |
NZ503401A (en) | Use of interferon-beta (IFN-B) genes for the treatment of cancer | |
GR3022080T3 (en) | T-cell receptor gene located within alpha locus and dna constructions | |
AU590861B2 (en) | New human lymphotoxin (TNF-beta) polypeptides their prepartion and use | |
EP0227604A3 (en) | Use of oligopeptides in the treatment of viral infections | |
AU3118095A (en) | Dna sequences coding for the human proteins tx and ty related to the interleukin-1beta converting enzyme | |
ZA95968B (en) | Interferon alpha/beta binding protein its preparation and use | |
AU7336687A (en) | Treatment of basal cell carcinoma intralesionally with recombinant human alpha interferon | |
PL313257A1 (en) | Novel tripeptides useful in treating immune system and central nervous system | |
MY131599A (en) | Use of il-10 to stimulate peripheral blood mononuclear cell cytolytic activity | |
AU4628289A (en) | Wound-induced dna sequence from solanum tuberosum and its use | |
ES8700694A1 (es) | Un procedimiento para producir un polipeptido de interferon hibrido antivirico y antiproliferante | |
Hsieh et al. | Cytostatic effect of interferon-gamma and monocyte against a human carcinoma cell line. | |
EP0303483A3 (en) | Novel lymphokine and compositions thereof | |
IT1262997B (it) | Composto proteico e sequenze nucleotidiche codificanti per esso. | |
ES8606788A1 (es) | Un procedimiento para la obtencion de sobrenadantes de leu- cocitos humanos con actividades inmunomoduladoras |